Deep dive on DPP-4 inhibitors with a focus on Trajenta® (linagliptin)

Deep dive on DPP-4 inhibitors

This eLearning module and the associated videos have been commissioned and funded by Boehringer Ingelheim. The module and associated videos contain promotional content. For UK healthcare professionals.

View Trajenta® (linagliptin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland

PC-GB-103189
Date of preparation: July 2021

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage